- Previous Close
0.0670 - Open
0.0690 - Bid 0.0700 x --
- Ask 0.0760 x --
- Day's Range
0.0690 - 0.0700 - 52 Week Range
0.0590 - 0.0900 - Volume
96,264 - Avg. Volume
14,703 - Market Cap (intraday)
5.261M - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Feb 7, 2025
- Forward Dividend & Yield 0.19 (258.75%)
- Ex-Dividend Date Dec 8, 2023
- 1y Target Est
--
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.
www.invextherapeutics.comRecent News: IXC.AX
View More
Performance Overview: IXC.AX
Trailing total returns as of 3/18/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IXC.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IXC.AX
View MoreValuation Measures
Market Cap
5.04M
Enterprise Value
-771.15k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.94
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
9.43%
Return on Assets (ttm)
-1.20%
Return on Equity (ttm)
2.14%
Revenue (ttm)
1.21M
Net Income Avi to Common (ttm)
114.36k
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.81M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-471.3k
Company Insights: IXC.AX
IXC.AX does not have Company Insights